Publication: Prevalence and risk factors for pulmonary hypertension in patients with hemoglobin E/β-thalassemia disease
Issued Date
2014-01-01
Resource Type
ISSN
16000609
09024441
09024441
Other identifier(s)
2-s2.0-84896548170
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
European Journal of Haematology. Vol.92, No.4 (2014), 346-353
Suggested Citation
Vichai Atichartakarn, Suporn Chuncharunee, Napaporn Archararit, Umaporn Udomsubpayakul, Ratchanee Lee, Anusith Tunhasiriwet, Katcharin Aryurachai Prevalence and risk factors for pulmonary hypertension in patients with hemoglobin E/β-thalassemia disease. European Journal of Haematology. Vol.92, No.4 (2014), 346-353. doi:10.1111/ejh.12242 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/34533
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Prevalence and risk factors for pulmonary hypertension in patients with hemoglobin E/β-thalassemia disease
Other Contributor(s)
Abstract
Objectives: To find the prevalence and risk factors of pulmonary hypertension (PHT) in adult patients with hemoglobin E/β-thalassemia disease (E/β-Thal). Methods: One hundred and ten clinically stable E/β-Thal outpatients, sixty-one of whom had undergone splenectomy, were prospectively studied using their clinical profiles, selected blood tests, chest roentgenogram, and transthoracic echocardiogram. Based on the pulmonary artery systolic pressure (PASP) values estimated by the echocardiogram of ≥36 mmHg, they were dichotomized into those with (PHT+) and without (PHT-) PHT. Results: PHT was found in 41 (37.3%) patients without gender preponderance. It was not due to the left heart and was not severe (PASP = 46.3 ± 10.4 mmHg). PASP was higher in splenectomized patients (48.0 ± 11 vs. 40.3 ± 4.7 mmHg (P = 0.004)). PHT was found in 32 of 61 (52.5%) splenectomized patients, mostly (53%) in the second decade, and rarely (6.3%) during the first 5 yr after splenectomy. PHT+ patients had more hemolysis (P = 0.001-0.04 depending on the parameters), more asplenic cases (P < 0.001), and higher serum soluble vascular cell adhesion molecule-1 (sVCAM-1) and high-sensitivity C-reactive protein levels (P = 0.004 and 0.008, respectively). Strong risk factors by univariate analysis were serum sVCAM-1 levels ≥1600 ng/mL, serum cell-free Hb ≥ 3 mg/dL, asplenia, and amount of NRBCs/100 WBCs >40. Conclusions: Prevalence of PHT in E/β-Thal patients was 37.3% without gender preponderance. Those with severe hemolysis and asplenia invariably had severer PHT. Strong risk factors were asplenia and associated markedly elevated values of sVCAM-1, cell-free Hb, and NRBCs in blood. © 2013 John Wiley & Sons A/S.
